A nootropic agent
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Meclofenoxate (hydrochloride)

Item No. 28283

Technical Information
Formal Name
2-(4-chlorophenoxy)-acetic acid, 2-(dimethylamino)ethyl ester, monohydrochloride
CAS Number
3685-84-5
Synonyms
  • Dimethylaminoethyl 4-chlorophenoxyacetate
  • Methocynal
Molecular Formula
C12H16ClNO3 • HCl
Formula Weight
Purity
≥95%
Formulation
A solid
DMF: 20 mg/mlDMSO: 33 mg/mlEthanol: 3 mg/mlPBS (pH 7.2): 10 mg/ml
λmax
226, 280, 288 nm
SMILES
ClC1=CC=C(OCC(OCCN(C)C)=O)C=C1.Cl
InChi Code
InChI=1S/C12H16ClNO3.ClH/c1-14(2)7-8-16-12(15)9-17-11-5-3-10(13)4-6-11;/h3-6H,7-9H2,1-2H3;1H
InChi Key
FIVHOHCAXWQPGC-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Product Description

    Meclofenoxate is a nootropic agent.1 It inhibits norepinephrine reuptake by isolated rat striatal synaptosomes (IC50 = 0.5 mM) and serotonin (5-HT) reuptake by isolated rat cortical synaptosomes (IC50 = 2.7 mM). Meclofenoxate increases survival of dopaminergic neurons in a C. elegans psd-1 knockdown model of Parkinson's disease.2 It reduces rotenone-induced depletion of dopamine and glutathione (GSH), lipid peroxidation, production of nitric oxide (NO), and cortical and cerebral damage, as well as enhances activity of catalase and superoxide dismutase in a rat model of Parkinson's disease when administered at a dose of 100 mg/kg.3 Meclofenoxate (100 mg/kg) increases synaptic surface density and reduces age-induced decreases in synaptic numerical density in aged rats.4 It also reduces neuronal lipofuscin pigment, a marker of aging, in the cerebral cortex and hippocampus and improves learning and memory in the T-maze in aged mice.5 Formulations containing meclofenoxate have been used in the treatment of senile dementia.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Stancheva, S.L., and Alova, L.G. Biogenic monoamine uptake by rat brain synaptosomes during aging. Effects of nootropic drugs. Gen. Pharmacol. 25(5), 981-987 (1994).

    2. Wang, S., Zhang, S., Xu, C., et alChemical compensation of mitochondrial phospholipid depletion in yeast and animal models of parkinson’s disease. PLoS One 11(10), e0164465 (2016).

    3. Verma, R., and Nehru, B. Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson’s disease. Neurochem. Int. 55(6), 369-375 (2009).

    4. Bertoni-Freddari, C., Giuli, C., and Pieri, C. The effect of acute and chronic centrophenoxine treatment on the synaptic plasticity of old rats. Arch. Gerontol. Geriatr. 1(4), 365-373 (1982).

    5. Nandy, K. Centrophenoxine: Efects on aging mammalian brain. J. Am. Geriatr. Soc. 26(2), 74-81 (1978).